10.5281/zenedo.15960797

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS

ISBN Number- 978-81-985724-7-9



Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

Chapter- 2

FORMULATION AND PHYSICAL-CHEMICAL FACTORS

MS. PRADNYA SUDAM VISHWE
Assistant Professor
PDEA's College of Pharmacy, Hadapsar, Pune.
Pin: 411028
Email: pradnyavishwe@gmail.com

MONIKA SHARMA
Assistant Professor
PDEA's College of Pharmacy, Hadapsar, Pune, Pin - 411028
Email: sharma.monika5593@gmail.com

DR. SHAHAJI SHIVAJI CHANDANSHIVE
Associate Professor
Shikshan Maharshi Guruvarya R G Shinde Mahavidyalaya, Paranda,
Dharashiv Maharashtra, Pin - 413502
Email: chandanshive75@gmail.com

MONALI ANIRUDDHA KOHINKAR
Assistant Professor
TMV's Lokmanya Tilak Institute of Pharmaceutical Sciences,
Mukund Nagar, Pune- 411037
Email: monalikalbhor3131@gmail.com

V. GEETHA
Lecturer in Chemistry
Government Degree College, RCPM, AP
Pin - 533255
Email: velalamgeetha@gmail.com

10.5281/zenedo.15960797

Chapter 2….

FORMULATION AND PHYSICAL-CHEMICAL FACTORS

MS. PRADNYA SUDAM VISHWE
Assistant Professor
PDEA's College of Pharmacy, Hadapsar, Pune.
Pin: 411028
Email: pradnyavishwe@gmail.com

MONIKA SHARMA
Assistant Professor
PDEA's College of Pharmacy, Hadapsar,
Pune, Pin - 411028
Email: sharma.monika5593@gmail.com

DR. SHAHAJI SHIVAJI CHANDANSHIVE
Associate Professor
Shikshan Maharshi Guruvarya R G Shinde Mahavidyalaya, Paranda,
Dharashiv Maharashtra, Pin - 413502
Email: chandanshive75@gmail.com

MONALI ANIRUDDHA KOHINKAR
Assistant Professor
TMV's Lokmanya Tilak Institute of Pharmaceutical Sciences,
Mukund Nagar, Pune- 411037
Email: monalikalbhor3131@gmail.com

V. GEETHA
Lecturer in Chemistry
Government Degree College, RCPM, AP
Pin - 533255
Email: velalamgeetha@gmail.com

The formulation and physical-chemical characteristics that control the active pharmaceutical ingredient's (API) bioavailability are just as important to the effectiveness of drug therapy as the API's inherent pharmacological activity. One of the most important factors in determining how much of a medicine is absorbed into the systemic circulation is the dissolution rate, or how quickly the drug dissolves in the gastrointestinal (GI) fluids. Particle size, solubility, crystal shape, and excipient selection are just a few of the variables that can greatly affect dissolving behavior [1]. This chapter explores the crucial elements of drug formulation and the dissolution process. It examines how dose forms might improve GI absorption and modulate drug release, emphasizing the significance of creating pharmaceutical solutions that maximize therapeutic results. Pharmaceutical scientists and formulators who want to create dependable and efficient oral dose forms must comprehend these concepts.

2.1 DISSOLUTION RATE AND PROCESS

A key idea in pharmaceutical sciences is the dissolution rate, which expresses how rapidly a medicinal material dissolves in a particular solvent under controlled circumstances [2]. It is a crucial factor in determining a drug's bioavailability, particularly for solid dosage forms like tablets and capsules that are taken orally. Formulators can maximize drug absorption and therapeutic efficacy by having a thorough understanding of the dissolution process.

2.1.1 Definition and Importance

In pharmaceutical sciences, dissolution is a crucial physicochemical process that describes how a solid medicine changes into a molecularly dispersed state in a solvent, usually gastrointestinal fluids. It is the first stage of the absorption of solid dose forms, including tablets and capsules, that are taken orally. Essentially, a medication cannot have its therapeutic effect if it does not dissolve since it cannot be absorbed through the gastrointestinal epithelium.

- **Fundamental Definition**

The process by which the active pharmaceutical ingredient (API) is liberated from a solid dosage form and enters solution in the gastrointestinal system is specifically referred to as dissolving in the context of pharmaceuticals. The physicochemical characteristics of the medication, the ingredients in the formulation, and the physiological conditions—such as pH, temperature, and GI tract motility—all have an impact on this process.

The Noyes-Whitney equation, which links the dissolution rate to the drug particles' surface area, saturation solubility, diffusion layer thickness, and concentration gradient, is frequently

used to characterize the rate of dissolution. Particularly with immediate-release formulations, a higher rate of dissolving frequently corresponds to a speedier beginning of effect.

- **Pharmacokinetic Relevance**

The dissolution process and a drug's bioavailability are closely related. The percentage of the supplied dose that enters the systemic circulation in an active form is known as bioavailability. The rate-limiting stage for absorption of medications taken orally is dissolution, especially when the agent has limited water solubility. In terms of absorption, drugs that fall within BCS Classes II and IV (Biopharmaceutical Classification System) are particularly restricted by their rate of dissolution.

Even a powerful medication may show therapeutic failure if dissolution is sluggish or incomplete because of insufficient plasma concentrations. However, quick and thorough breakdown promotes greater absorption, which in turn leads to better patient adherence, lower dosage frequency, and optimal therapeutic effectiveness.

- **Clinical and Regulatory Importance**

Regulatory bodies such as the U.S. FDA, EMA, and WHO also acknowledge the significance of dissolving and mandate in vitro dissolution testing as a stand-in for in vivo bioavailability studies, especially in formulation development and quality control. It is used to create in vitro-in vivo correlations (IVIVC), which aid in forecasting the medication's behavior in the human body based on lab-scale experiments, and it functions as a critical quality attribute (CQA) in the assessment of generic drug products.

Dissolution testing is an essential tool for guaranteeing therapeutic equivalency and patient safety because it can also reveal formulation irregularities, manufacturing flaws, or batch-to-batch variability.

- **Therapeutic Impact**

From a therapeutic standpoint, a drug with optimized dissolution characteristics ensures:

- Rapid onset of action in acute treatments (e.g., analgesics).
- Consistent and predictable absorption, minimizing inter-patient variability.
- Reduced risk of dose dumping in modified-release formulations.
- Improved efficacy in chronic therapies due to better bioavailability.

2.1.2 The Noyes–Whitney Equation

The dissolution rate can be mathematically described by the **Noyes–Whitney equation**:

$$\frac{dC}{dt} = \frac{DA(C_s - C)}{h}$$

Where:

- **dC/dt** is the rate of dissolution,
- **D** is the diffusion coefficient of the drug,
- **A** is the surface area of the drug exposed to the solvent,
- **Cs** is the saturation solubility of the drug,
- **C** is the concentration of the drug in the solution at time t,
- **h** is the thickness of the diffusion layer.

This formula shows how the dissolving rate is affected by a number of variables, including surface area, solubility, and diffusion layer thickness [3]. During formulation, it provides a basis for comprehending and adjusting drug release characteristics.

2.1.3 Dissolution vs. Solubility

Differentiating between solubility and dissolution rate is crucial. The maximum amount of medicine that may dissolve in a solvent at equilibrium is known as solubility, and the pace at which this process takes place is known as the dissolution rate. A tiny surface area or unfavourable formulation conditions might cause a medicine that is highly soluble to dissolve slowly, and vice versa.

2.1.4 In Vitro Dissolution Testing

Under standardized settings, USP equipment (such as a paddle or basket) is frequently used for in vitro dissolving experiments. For quality assurance and in vivo performance prediction, these tests are essential. The information gathered is utilized to design formulations, verify consistency between batches, and establish in vitro-in vivo correlations (IVIVC).

2.1.5 Impact on Bioavailability

One of the most important factors influencing a medication's therapeutic effectiveness is its bioavailability, which is the percentage of the dose that enters the bloodstream in an active state. The rate of dissolution is crucial for many medications [4], especially those with low water solubility. This is particularly important for medications that fall into Class II and Class IV of the Biopharmaceutics Classification System (BCS), which are distinguished by their poor solubility.

➢ **Dissolution as the Rate-Limiting Step in Absorption**

The capacity of BCS Class II medications (low solubility, high permeability) to penetrate biological membranes is not a significant barrier; rather, dissolution is the bottleneck. Even a medication with great permeability cannot be sufficiently absorbed without appropriate dissolution, which results in variable or inadequate bioavailability.

The difficulty is even worse with BCS Class IV medications (poor solubility and low permeability), since both dissolution and membrane penetration are troublesome. But even in these situations, improved absorption requires first improving dissolution.

➢ **Techniques to Enhance Dissolution and Improve Bioavailability**

A variety of **formulation strategies** have been developed to enhance the dissolution rate of poorly soluble drugs, thereby increasing their bioavailability:

- **Particle Size Reduction**: By micronizing or nanonizing drug particles, the surface area available for dissolution increases, leading to a faster and more complete release into solution. Techniques such as **wet milling, high-pressure homogenization**, and **ultrasonication** are commonly used.
- **Salt Formation**: Converting the drug into a more water-soluble salt form (e.g., converting a free base to a hydrochloride salt) can improve dissolution characteristics significantly.
- **Solid Dispersion**: Dispersing the poorly soluble drug in an inert hydrophilic carrier (like polyethylene glycol or PVP) in the solid state can enhance wettability, reduce crystallinity, and accelerate dissolution.
- **Use of Surfactants and Solubilizers**: Incorporating agents like sodium lauryl sulfate or polysorbates can reduce surface tension and promote better interaction of the drug with the aqueous environment.
- **Amorphous Formulation**: Drugs in the amorphous (non-crystalline) state generally dissolve more readily than their crystalline counterparts due to higher energy and greater molecular mobility.

➢ **Clinical Significance of Improved Dissolution**

Improving the dissolution rate and, consequently, the bioavailability of a drug can result in:

- **Faster onset of action**, particularly beneficial in drugs used for acute conditions (e.g., analgesics, antipyretics).

- **Greater therapeutic effectiveness**, allowing lower doses to achieve the desired plasma concentrations.
- **Reduced dosing frequency**, improving patient compliance.
- **Minimized food effects**, which can otherwise influence drug solubility and absorption when taken with meals.
- **Enhanced consistency in therapeutic response** across patient populations.

➢ **Regulatory and Developmental Considerations**

Dissolution testing is a crucial component of quality control and drug development from a regulatory perspective. Dissolution tests help forecast in vivo performance for BCS Class II medications since in vitro-in vivo correlation (IVIVC) is frequently attainable. As long as dissolution profiles match, this allows regulatory bodies to assess the bioequivalence of innovator and generic products without the need for lengthy clinical trials.

2.2 FACTORS AFFECTING DISSOLUTION RATE

There are several physicochemical and formulation-related factors that affect a drug's rate of dissolution. Comprehending these factors is essential for creating reliable and efficient pharmaceutical products [5], especially for solid dosage forms that are taken orally. Enhancing these variables guarantees increased bioavailability, medicinal efficacy, and batch consistency.

2.2.1 Particle Size and Surface Area

The size of the particles has a significant impact on how quickly a medicine dissolves in biological fluids. The Noyes–Whitney equation, which states that the dissolving rate is directly proportional to the surface area of the drug exposed to the solvent, controls the link between particle size and dissolution rate. Faster dissolving is made possible by smaller particles' higher surface area-to-volume ratio, which enables more drug molecules to interact with the surrounding media at any one time.

This idea is especially crucial in pharmaceutical formulations for medications that are poorly soluble in water, which is a feature shared by many contemporary APIs. These medications' bioavailability is impacted when they are in big crystalline forms because of their restricted surface area, which hinders disintegration. Particle size reduction greatly increases surface area, which promotes better absorption throughout the gastrointestinal tract, faster medication release, and increased wetting.

10.5281/zenedo.15960797

Micronization, in which the drug particles are mechanically reduced to micrometer-sized dimensions, is one often used strategy to take advantage of this phenomena. Even more sophisticated is nanonization, which uses methods like wet milling or high-pressure homogenization to further reduce the particle size into the nanoscale range. Because they have a much larger surface area and can stay suspended in the GI fluids for longer, these nanosized drug particles have better dissolving profiles, which helps with absorption even more.

Particle size reduction is not without difficulties, though. The formulation may be compromised by problems like aggregation, electrostatic charges, or instability caused by extremely small particles. In order to preserve dispersion and stop particle development or precipitation, stabilizers or surfactants are frequently added.

2.2.2 Solubility of the Drug

A drug's solubility is a key factor in determining how quickly it dissolves and, in turn, how bioavailable it is. The highest concentration of a solute that may dissolve in a solvent at a particular temperature and create a saturated solution is known as intrinsic solubility.



Figure 1: Drug Solubility

The drug's physicochemical characteristics and chemical structure dictate its solubility. Because they dissolve more slowly, drugs with low solubility have a difficult time reaching acceptable blood concentrations, which can result in inadequate therapeutic efficacy.

- **Impact of Low Solubility on Dissolution**

Low intrinsic solubility medications frequently have slow rates of dissolution, which can lead to restricted GI tract absorption. Low-solubility medications have a sluggish rate of dissolution

because they are difficult to dissolve in gastrointestinal fluids, even when particle size is decreased to enhance surface area. This gradual dissolving may result in partial or delayed absorption, which would lower the drug's bioavailability and possibly jeopardize its therapeutic benefits. Therefore, especially for oral dosage forms, a drug's solubility plays a crucial role in determining how well it may be absorbed into the bloodstream.

- **Strategies to Enhance Solubility**

To overcome solubility challenges, various techniques are employed during formulation development. Some of the most common approaches include:

1. **Salt Formation**: Salt production is a commonly used technique to increase the solubility of medications that are mildly basic or acidic. It is frequently possible to increase the drug's solubility by turning it into a salt form. Better dissolution rates and bioavailability result, for example, from the sodium salt of a weak acid or the hydrochloride salt of a weak base dissolving more easily in water than the free base or acid form.
2. **Complexation**: Using complexing agents, such cyclodextrins, to improve solubility is an additional strategy. Cyclodextrins are cyclic oligosaccharides that have the ability to combine with lipophilic drug molecules to form inclusion complexes, which increases the solubility of the drug in aqueous solutions. This method allows for greater absorption in the GI system and is especially helpful for medications with limited water solubility.
3. **Use of Co-solvents**: To increase the solubility of poorly soluble medications, co-solvents—extra solvents—can be combined with the primary solvent, which is typically water. For instance, lipophilic medications may be made more soluble in an aqueous solution by using organic solvents such as ethanol or propylene glycol. This method is frequently applied for creating oral or injectable solutions where quick dissolving is necessary for the medicine to be properly absorbed.
4. **Micronization and Nanomilling**: A drug's surface area can be increased by decreasing its particle size, which helps speed up disintegration. By giving the drug more surface area to interact with the solvent, methods like micronization (reducing particle size to the micrometer range) and nanomilling (reducing particle size to the nanometer range) can speed up the dissolution of poorly soluble medications.

- **Solubility and its Influence on Bioavailability**

Because it directly affects a drug's ability to reach the systemic circulation after administration, the link between solubility and bioavailability is vital [6]. Drugs with poor solubility may not dissolve sufficiently in the GI tract to achieve appropriate plasma concentrations because the dissolving process is the initial step in the absorption process for oral medications. As a result, despite the drug's potential potency, its limited bioavailability may prevent it from having the intended therapeutic benefits.

Furthermore, solubility is influenced by the gastrointestinal tract's pH. Weak bases may dissolve easier in the somewhat basic environment of the small intestine, whereas weak acids are generally more soluble in the stomach's acidic environment. By taking into consideration this pH-dependent solubility, formulation techniques can improve the drug's solubility profile in various GI tract locations.

- **Clinical Implications of Solubility Enhancement**

Improving the solubility of medications that are poorly soluble can greatly increase their effectiveness and improve patient outcomes. Solubility-enhancing techniques facilitate more rapid and thorough absorption by raising dissolution rates, which may result in a quicker beginning of action and a decrease in the frequency of administration. In order to decrease variability in clinical responses, guarantee uniform drug delivery, and reach therapeutic plasma concentrations, medicines with low solubility can be formulated using solubility-enhancing procedures.

The exact physicochemical characteristics of the medication, the intended route of administration, and the expected therapeutic outcome all influence the method selection; therefore, these tactics must be carefully tuned. For instance, not all drugs can benefit from salt formation, and co-solvents might increase solubility but can also present problems with formulation stability or possible toxicity.

2.2.3 Polymorphism and Crystalline Structure

The ability of a medicinal molecule to exist in several crystal forms, each with unique chemical configurations or crystal lattices, is known as polymorphism. Polymorphs are these variations of the same chemical molecule [7]. Significant differences in the drug's solubility, rate of dissolution, stability, and bioavailability can result from variations in the crystal structure. Since polymorphism directly affects the drug's therapeutic efficacy, it is crucial to comprehend and manage it during the formulation development process.

- **Amorphous vs. Crystalline Forms**

The difference between crystalline and amorphous forms is one of the most significant in medication polymorphism. The molecules in amorphous pharmaceuticals are placed randomly because they lack a clear crystal structure. Since the drug's molecular bonds are weaker and more easily broken in this disorganized state than in crystalline versions, dissolution is usually accelerated. Because amorphous medications dissolve more readily, they are absorbed into the bloodstream more quickly, which frequently results in a quicker beginning of action.

In contrast, the molecules of crystalline medicines are grouped in a repeating lattice pattern, giving them a highly ordered molecular structure. It usually takes more energy to break up this crystalline structure, which might result in slower rates of dissolution and less water solubility. Because of this, crystalline forms typically absorb more slowly, which may postpone the effects of treatment.

- **Impact of Polymorphism on Dissolution Rate**

A drug's polymorphic shape can have a big impact on how quickly it dissolves and, in turn, how bioavailable it is. Sometimes a polymorph with a more solid crystalline structure will be less soluble, which will cause it to dissolve more slowly. On the other hand, a less stable polymorph—which might be more amorphous—might dissolve more quickly, but it might also experience problems with physical stability over time, such as changing into a more stable form when handled or stored.

Because it has a direct impact on the medicine's performance, choosing the appropriate polymorphic form during drug formulation is essential. For example, an amorphous form may be selected to optimize solubility and bioavailability when a medicine is intended for immediate-release formulations. On the other hand, in order to regulate the drug's release rate in controlled-release or extended-release formulations, a more stable crystalline form might be selected.

- **Polymorphic Conversion and Stability**

During the manufacture or storage of the substance, polymorphic conversion may take place under several circumstances. Pressure, temperature, humidity, and mechanical stress are some of the variables that might cause a medication to change from one polymorphic form to another. For instance, a medication may undergo polymorphic transition during long-term storage or crystallize into a more stable polymorph during production, which would alter its rate of dissolution and, eventually, its bioavailability. For medications that depend on specific

dissolving properties to produce the intended therapeutic effects, this change may be very troublesome.

Monitoring and managing the drug's crystalline form at every stage of its life cycle—from initial formulation to final product storage—is essential to preventing these problems. Choosing the right stabilizing agents, like amorphous stabilizers or polymorph inhibitors, can also help keep the drug's desired dissolving profile and stop unwanted polymorphic alterations.

- **Polymorphism in Drug Development**

Polymorph selection plays a crucial role in drug development because of the impact polymorphism has on pharmacological performance. To select the medicine that will provide the optimal combination of solubility, stability, and dissolving properties for the desired therapeutic application, researchers must carefully assess the many polymorphic forms of the drug. Furthermore, polymorphism screening is a crucial step in the preformulation phase, where several drug forms are examined for their physicochemical characteristics, such as stability, melting point, and solubility [8].

Furthermore, information about polymorphs and how they affect a drug's performance must be submitted to regulatory bodies like the FDA and EMA. This guarantees that throughout the drug's lifecycle, the selected polymorphic form will consistently deliver quality, efficacy, and safety.

2.2.4 Wettability and Hydrophobicity

One essential characteristic that greatly affects a drug's dissolving behavior is wettability. When a liquid (usually the dissolution media) spreads and stays in touch with a solid surface—in this case, the solid drug particle—it is said to have this property. The drug particles must initially make close contact with the dissolution medium in order for dissolution to take place. The drug's surface is wet, which makes it easier for the solvent to enter and dissolve the drug molecules. This process can be hampered by poor wettability, which can result in sluggish or partial dissolution.

- **Impact of Hydrophobicity on Wettability**

One important factor influencing a drug's wettability is its hydrophobicity. Drugs that are hydrophobic, or weakly soluble in water, have a tendency to withstand soaking and either float on the surface of the dissolving media or agglomerate. Because hydrophobic materials lack the essential contact forces with water molecules, it is difficult for the liquid to pass through the

solid surface, resulting in this behavior. As a result, the drug's bioavailability may be greatly decreased and the dissolving process is impeded.

Due to their slow or partial disintegration, hydrophobic medicines frequently show poor absorption in the gastrointestinal tract. This is especially troublesome for pharmaceuticals with low solubility (BCS Class II and IV drugs). Their incapacity to quickly breakdown in the stomach or intestines restricts their availability for bloodstream absorption, which affects the medication's therapeutic effectiveness.

- **Formulation Strategies to Improve Wettability**

Pharmaceutical formulators use a variety of techniques to improve the wettability of poorly soluble medications in order to get around the problems caused by hydrophobicity. Adding wetting agents or surfactants to the formulation is one of the most used methods. The surface tension between the solid drug particle and the dissolution media is decreased by surfactants such sodium lauryl sulfate (SLS), polysorbates, and tween compounds. This decrease in surface tension facilitates the solvent's easier entry into the drug particle, hence accelerating dissolution.

Wetting agents such as sodium stearate or polyethylene glycol (PEG) can be utilized in addition to surfactants. These agents work by altering the surface characteristics of the drug, making it more receptive to hydration and better able to interact with the dissolution medium. Enhancing wettability speeds up the rate of dissolution [9], enhancing absorption and therapeutic efficacy.

- **Solid Dispersions and Nanotechnology**

Using solid dispersions or formulations based on nanoparticles is another cutting-edge method to improve the wettability of hydrophobic medications. By dispersing the hydrophobic medication in a water-soluble carrier, solid dispersions enhance the surface area that can dissolve the medicine. This increases the drug's rate of dissolution and makes it more soluble in water. The creation of nanoparticles or nanocrystals, which have a substantially bigger surface area than their larger counterparts and so promote rapid dissolution, is another application of nanotechnology.

Nanotechnology improves wettability and increases the drug's thermodynamic solubility by decreasing particle size, which leads to more reliable and effective absorption.

2.2.5 Drug Form and Salt Formation

A drug's solubility and rate of dissolution are mostly determined by its chemical form, which also has an impact on its bioavailability. Whether the drug is in its free base form or a salt form

is one of the most crucial considerations in this situation. In order to improve the aqueous solubility of medications, especially those that are poorly soluble in water when in their free base form, salt production is frequently used[10].

In comparison to its free base form, a medication that is manufactured as a salt usually shows better dissolving characteristics. The electrostatic interactions between the salt's cation and anion, which promote improved solubility in water, are what cause this enhancement. The medicine is more ionized in the salt form, which facilitates its dissolution in the gastrointestinal tract's aqueous environment. Consequently, medications in their salt form have a tendency to dissolve more quickly, perhaps increasing their bioavailability.

For instance, the sodium salts of acidic medications frequently dissolve much more quickly than their free acid equivalents. The drug can dissociate more easily and enter the bloodstream more effectively due to its higher solubility in water. This idea also applies to basic medications, where salts like sulfates or hydrochlorides are frequently created to enhance solubility and dissolution.

The salt selection can affect the drug's stability and manufacturing qualities in addition to its solubility. A drug's physicochemical stability during storage can be enhanced by salt production, which also helps to avoid problems like oxidation or hydrolysis, which are frequent problems for pharmaceuticals in their free base forms. Moreover, salt creation may speed up the crystallization process during drug formulation, producing more consistent and controllable powders for the production of tablets or capsules.

It is crucial to remember that not all medications can be solved by salt production. The solubility benefit of salts may not always be as noticeable, particularly for medications with unusual chemical properties or those that are very lipophilic. Furthermore, when the medication is given orally or parenterally, the presence of salts may cause problems with osmolarity and irritation. The intended application of the medication, its physicochemical characteristics, and the planned pharmacokinetic results must all be taken into account when choosing the right drug form, whether it be as a free base or a salt.

2.2.6 pH of the Dissolution Medium

The solubility and ionization behavior of pharmaceuticals, especially weak acids or weak bases, are greatly influenced by the pH of the dissolution medium. The drug's ability to exist in its ionized or unionized state, which is mostly controlled by the pH of the surrounding environment, affects solubility. Weak acids and bases' pH-sensitive solubility can have a big

influence on how quickly they dissolve from their dose form, which can change how well they are absorbed and how bioavailable they are overall.

- **Effect of pH on Weak Acids and Bases**

In increasingly alkaline (basic) settings, weak acids tend to become more soluble. This is because ionized medications are frequently more soluble than their unionized counterparts, and weak acids are more prone to be ionized at higher pH values. On the other hand, weak bases dissolve more readily in acidic environments because they are less ionized. The absorption of a weak acid, such as aspirin, may be limited in the gastric phase because it dissolves more easily in the alkaline small intestine than in the acidic stomach.

Predicting the drug's dissolving behavior thus requires an understanding of how it interacts with various pH levels in the gastrointestinal (GI) tract. Whether using controlled-release or immediate-release formulations, this information can help formulate oral medication solutions to maximize absorption at particular locations throughout the GI tract.

- **Gastrointestinal pH Variability and Its Impact on Drug Absorption**

Because the gastrointestinal tract is made up of diverse parts with varying pH levels, there can be a lot of variation in how medications dissolve and are absorbed. The small intestine is more alkaline, with a pH range of 6 to 8, while the stomach is normally more acidic, with a pH range of 1-3. Because they may dissolve differently depending on where they are in the GI system, this variability poses problems for creating medications that are either weak acids or bases.

For instance, medications meant to be absorbed in the small intestine might benefit from formulations that dissolve easily in the alkaline environment of the intestine but stay intact in the stomach's acidic environment. This is a crucial factor for enteric-coated formulations, in which the coating prevents the medication from dissolving in the stomach and only permits release in the small intestine's higher pH environment.

- **Implications for Targeted Release Formulations**

When creating targeted drug delivery systems, the impact of pH on dissolution is especially crucial. pH-sensitive coatings or polymers can be used in these formulations to regulate the drug's release at particular GI tract locations. To guarantee that the medicine is released at the location where it will have the best solubility and absorption, a drug that is weakly basic or acidic may, for example, be encapsulated in a coating that dissolves only under specific pH circumstances.

For instance, coatings that are resistant to acidic environments but disintegrate at the higher pH found in the colon can be used for medications intended for colon-specific delivery. These methods are essential for treating conditions like colorectal cancer and inflammatory bowel disease (IBD) that call for local medication action in the colon. Formulators can minimize negative effects and maximize therapeutic results by carefully crafting the drug's pH-dependent release patterns.

2.2.7 Use of Excipients

Formulation excipients like binders, disintegrants, lubricants, and glidants play essential roles in modifying the dissolution rate. For example:

- **Disintegrants** (e.g., croscarmellose sodium) promote rapid tablet breakup, increasing surface area.
- **Hydrophilic excipients** aid in wetting and solubilization.
- **Hydrophobic lubricants** (e.g., magnesium stearate) may form water-repellent films, hindering dissolution if use excessively.

2.2.8 Manufacturing Processes

The pace at which the drug dissolves is significantly influenced by the manufacturing process of solid dosage forms, such as tablets and capsules. The drug's physical characteristics, including its particle size, porosity, surface area, and moisture content, can be altered by various production processes. These changes have an immediate effect on how rapidly the drug dissolves in the gastrointestinal tract. Therefore, the choice of manufacturing procedure is crucial for maximizing a drug's solubility and consequent bioavailability.

- **Compression Force and Tablet Hardness**

The compression force used during the tableting process is one of the most crucial elements in tablet manufacture. The tablet's compactness and hardness are determined by the compression force. Because of their solid structure, which prevents dissolving media from penetrating, tablets that are crushed too firmly may have limited porosity and sluggish breakdown rates. Softer tablets with more porosity, on the other hand, disintegrate more quickly, enabling a faster release of the medication into the gastrointestinal fluids. On the other hand, an overly soft tablet could degrade too quickly, resulting in irregular medication delivery. Therefore, to balance tablet strength and dissolve performance, the ideal compression force is required.

➢ **Granulation Techniques**

The granulation technique used during the formulation process can also significantly affect the dissolution rate. Granulation is a process where powders are bound together to form larger particles, improving the flow and compaction properties of the drug powder. There are two main types of granulations: wet granulation and dry granulation.

- **Wet Granulation**: With this method, granules are created using a liquid binder and subsequently dried. Wet granulation can enhance powder flow and homogeneity, but it can also make particles more cohesive, which lowers porosity and slows down dissolution. Because wet granulation usually produces more compact granules, it is more difficult for dissolution fluids to enter and dissolve the drug particles. This might not be the best option for medications that need rapid release, but it might be advantageous for controlled-release formulations when a slower dissolving is preferred.
- **Dry Granulation**: In contrast to wet granulation, dry granulation forms granules without the use of moisture by using mechanical force (such as roller compaction). Compared to wet granulation, this technique tends to maintain the drug particles' inherent characteristics while enabling a quicker disintegration. The granules are typically more porous due to the absence of an additional binder or moisture, which improves medication release by allowing dissolving medium to penetrate more effectively.

➢ **Drying Method and Moisture Content**

The dissolve rate is also influenced by the drying technique employed in the granulation and tablet manufacturing processes. The degree of hydration of the excipients and medication particles in wet granulation can be impacted by the application of heat or air drying to remove excess moisture from the granules. The surface area accessible for disintegration may be decreased by excessive drying, which might result in the development of hard granules or extremely compact tablets. On the other hand, tablets with a high moisture content due to inadequate drying may disintegrate too quickly or behave differently when dissolved.

One important component of dissolving is the final tablet's moisture content. Excessive moisture can make the medicine and excipients unstable, which can affect the dissolving profile or induce deterioration. Conversely, brittle pills that do not disintegrate as planned could result from inadequate moisture, which would prevent the medication from being released.

➢ **Impact on Immediate vs. Modified Release**

Depending on whether the formulation is meant for immediate-release or modified-release, the production processes—in particular, the granulation and compression techniques—can have varying effects. Fast dissolving is preferred in immediate-release formulations in order to guarantee a prompt commencement of pharmacological action. In these situations, methods that maintain the integrity of the drug particle—like direct compression—are typically favored in order to facilitate quicker release.

Slower dissolving is frequently preferred for modified-release formulations, such as controlled-release or extended-release tablets, in order to increase the duration of the drug's activity. Manufacturing techniques like wet granulation or the use of excipients with controlled-release qualities that provide higher particle cohesiveness or lower porosity may be advantageous in these situations. To further regulate the dissolution profile, the formulation may further make use of matrix systems or rate-controlling membranes.

2.3 ROLE OF DOSAGE FORMS IN GASTROINTESTINAL ABSORPTION

The rate and degree of drug absorption in the gastrointestinal (GI) tract are significantly influenced by the dose type of the medication [11]. The drug's release, dissolution, and eventual absorption into the systemic circulation are all influenced by the dosage form selection. Optimizing therapeutic efficacy and reducing medication response variability require an understanding of how dosage form design and GI physiology interact.

2.3.1 Solid Dosage Forms: Tablets and Capsules

Because of their high patient compliance, stability, and ease of administration, solid oral dosage forms—such as tablets and capsules—are the most popular and commonly utilized drug delivery methods. These dosage forms have many benefits, including a long shelf life, the potential to be mass-produced at a relatively low cost, and the ease of taking them without requiring medical assistance. The disintegration, dissolution, and solubilization processes that take place once the dosage form enters the gastrointestinal (GI) tract, however, are just as important to the therapeutic efficacy of these forms as their chemical makeup.

➢ **Immediate-Release (IR) Formulations**

The purpose of immediate-release (IR) tablets and capsules is to release the medication quickly after consumption, facilitating rapid bloodstream absorption. In the stomach's acidic environment, these formulations usually dissolve fast, making the active pharmaceutical ingredient (API) easily absorbed in the upper gastrointestinal tract. IR formulations are

designed to have a rapid beginning of action, which makes them appropriate for conditions that need immediate treatment, including analgesics or antipyretics.

IR formulations' quick absorption and dissolution, however, might occasionally result in varying drug plasma levels, which may call for repeated dosing to maintain therapeutic levels. Peak-and-trough effects may result from this variation in plasma concentrations, raising the possibility of adverse effects or decreasing the drug's overall efficacy. As a result, although while IR formulations have rapid therapeutic effects, they might not be the best choice for disorders that call for consistent medication levels over time.

- **Modified-Release (MR) Formulations**

By changing the rate, time, or place of drug release, modified-release (MR) formulations—such as extended-release (ER) or delayed-release (DR) tablets and capsules—have been created to overcome the drawbacks of IR formulations. These formulations are made especially to reduce the frequency of doses, maintain steady therapeutic plasma levels, and extend a drug's duration of action.

In order to provide a long-lasting therapeutic impact, extended-release (ER) tablets or capsules are designed to release the medication gradually over time. By maintaining more stable plasma medication concentrations, this extended release lessens the need for frequent dosing and enhances patient adherence [12]. For instance, ER formulations are frequently employed in the treatment of long-term illnesses like diabetes, hypertension, and chronic pain. ER formulations can improve patient outcomes and better regulate symptoms by sustaining a consistent medication concentration throughout time.

Conversely, delayed-release (DR) formulations are made to release the medication at a certain location in the gastrointestinal tract, usually after avoiding the stomach's acidic environment. When a medication is meant to be absorbed in the gut or would be broken down or rendered inactive by stomach acid [13], DR tablets are utilized. For instance, some medications that cause irritation to the stomach lining or are unstable in the stomach's acidic environment can be made into DR tablets, which release the medication only after it enters the small intestine, where the conditions are better for absorption. These formulations are frequently employed to treat disorders where site-specific drug administration is required, such as ulcerative colitis or gastroesophageal reflux disease (GERD).

- **Challenges and Considerations in Formulation**

The drug's physicochemical characteristics, including its solubility, stability, and permeability, are critical to the efficacy of both IR and MR formulations. Drugs with limited solubility, for example, may dissolve poorly [14], which lowers their bioavailability and therapeutic efficacy. Furthermore, to make sure that the changed release mechanism is in line with the drug's intended action, MR formulations must carefully take into account the drug's half-life, absorption profile, and intended therapeutic effect.

The effectiveness of MR formulations can also be impacted by biological variables as intestinal motility, stomach emptying time, and GI pH fluctuations. Because of this heterogeneity, formulation and dose must take into account the unique characteristics of each patient, such as age, diet, or medical conditions, in order to guarantee consistent therapeutic results.

2.3.2 Liquid Dosage Forms: Solutions and Suspensions

Because they have a quicker beginning of action than solid dosage forms like tablets and capsules, liquid dosage forms like solutions and suspensions are frequently utilized in pharmaceutical formulations. The main benefit of liquid forms is that they can avoid the breakdown process that solid forms must go through, which increases the drug's absorption availability. This enhances bioavailability, especially for individuals who need quick therapeutic effects or who might have trouble swallowing tablets.

- **Solutions: Enhanced Bioavailability**

The active pharmaceutical ingredient (API) is fully dissolved in an appropriate solvent in solutions, which are liquid formulations. Because the medication is already molecularly dispersed in oral solutions, the gastrointestinal (GI) tract can absorb it straight. Since the medicine doesn't have to dissolve or disintegrate, it can be absorbed right away, which frequently leads to higher bioavailability and faster absorption than with solid dosage forms. Because of this feature [15], solutions are especially helpful when quick therapeutic action is needed, including in emergency treatments for acute illnesses, infections, or discomfort.

Because the dissolved drug is instantly in the form needed for absorption across the GI mucosa, medications in solution formulations usually have a higher bioavailability. Because absorption rates are frequently steady and predictable, treatment results are more dependable. Solutions are a recommended option for pediatric and geriatric groups where solid forms may be difficult to swallow and the medicine is available in its already-dissolved state.

- **Suspensions: Drug Particles and Dissolution**

Drug particles that have not dissolved are suspended in a liquid media in suspensions as opposed to solutions. Before these particles may be absorbed, they must first dissolve in the GI juices. Suspensions are usually employed for medications that are insoluble in water, however for best results, additional formulation techniques are needed. In suspensions, the drug's particle size plays a crucial role in determining the rate of dissolution and, in turn, the drug's absorption. Because of their larger surface area, smaller particles may dissolve more quickly and absorb more effectively.

Pharmaceutical chemists frequently add suspending agents to suspension formulations in order to further enhance the solubility and homogeneity of absorption. By keeping the drug particles dispersed uniformly throughout the liquid, these agents help to avoid settling and guarantee that the active component is present in a constant amount in every dosage. Wetting agents can also be employed to improve the interaction between the drug particles and the solvent, which will speed up the suspension's dissolution in the gastrointestinal system.

Suspensions have the benefit of enabling the delivery of medications that are poorly soluble, but they also present some difficulties. These include the possibility of varying absorption rates because to variations in the pace at which the drug particles dissolve, as well as the necessity of cautious handling and storage to avoid sedimentation[16].

- **Key Considerations in Formulation**

The drug's physicochemical characteristics frequently influence the decision between a suspension and a solution. While drugs with poor solubility may be manufactured as suspensions to aid in distribution, highly soluble drugs are better suited for solution formulations. Additionally, because the drug is already in a homogenous form, solutions are simpler to manufacture in terms of stability and dosing accuracy. Suspensions, on the other hand, might offer a good substitute for poorly soluble medications; nevertheless, they need to be carefully handled to guarantee that the drug particles are uniformly distributed and easily absorbed in the body.

When compared to solid dose forms, the quick beginning of action of both solutions and suspensions is favorable. They offer versatile and efficient distribution choices, especially for elderly, pediatric, and other patient populations that can profit from liquid formulations. In the end, the particular pharmacological properties, therapeutic objectives, and patient requirements will determine which of these two liquid dose forms is best.

2.3.3 Gastroretentive Dosage Forms

The purpose of gastroretentive systems is to extend the drug's duration of residence in the stomach or upper gastrointestinal tract. These consist of high-density formulations that withstand stomach emptying, mucoadhesive systems, and floating tablets. These methods are especially helpful for medications with limited absorption windows or those that are mostly absorbed in the stomach or proximal small intestine[17].

For medications with constrained absorption windows, these dosage forms can increase bioavailability, decrease dosing frequency, and improve therapeutic effects by lengthening the stomach retention period.

2.3.4 Enteric-Coated Dosage Forms

Tablets or capsules with an enteric coating are designed to survive the stomach's acidic pH and only release their contents in the intestine's more neutral or alkaline environment. For medications that are unstable in acidic environments (like proton pump inhibitors) or that aim to reduce stomach discomfort (like NSAIDs), this is essential.

The active ingredient is shielded by enteric coatings while it passes through the stomach, facilitating the best possible absorption in the small intestine.

2.3.5 Nanotechnology-Based Dosage Forms

Recent developments in nanotechnology have produced dosage forms based on nanoparticles, including polymeric nanoparticles [18], liposomes, and nanocrystals. By enhancing their interaction with biological membranes and promoting transcellular uptake, these systems improve the solubility, stability, and absorption of medications that are poorly soluble in water.

Additionally, by providing chances for controlled release and targeted administration, nanocarriers greatly improve oral bioavailability and lessen systemic side effects [19].

2.3.6 Influence of Dosage Form on First-Pass Metabolism

Exposure to first-pass metabolism in the gut wall and liver can be influenced by the dosage form's composition and route[20]. For example, by directly entering into the systemic circulation through mucosal tissues, sublingual or buccal formulations can circumvent the first-pass effect. For medications that are heavily processed in the upper gastrointestinal tract, formulations intended for colon-targeted delivery may also increase bioavailability by lowering pre-systemic metabolism.

BIBLIOGRAPHY

1. Boddu, R., Kollipara, S., Bhattiprolu, A. K., & Ahmed, T. (2023). Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics–a case study and utility in regulatory justifications. *Xenobiotica*, *53*(10-11), 587-602.
2. Boddu, R., Kollipara, S., Vijaywargi, G., & Ahmed, T. (2023). Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions. *Xenobiotica*, *53*(4), 260-278.
3. Bonam, S. R., Sekar, M., Guntuku, G. S., Nerella, S. G., Pawar A, K. M., Challa, S. R., ... & Mettu, S. (2021). Role of pharmaceutical sciences in future drug discovery. *Future Drug Discovery*, *3*(3), FDD64.
4. Boutin, J. A., Witt-Enderby, P. A., Sotriffer, C., & Zlotos, D. P. (2020). Melatonin receptor ligands: a pharmaco-chemical perspective. *Journal of pineal research*, *69*(3), e12672.
5. Boyanapalli, S. S., Huang, Y., Su, Z., Cheng, D., Zhang, C., Guo, Y., ... & Kong, A. N. (2018). Pharmacokinetics and Pharmacodynamics of Curcumin in regulating anti-inflammatory and epigenetic gene expression. *Biopharmaceutics & drug disposition*, *39*(6), 289-297.
6. Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019). Apixaban: a clinical pharmacokinetic and pharmacodynamic review. *Clinical pharmacokinetics*, *58*, 1265-1279.
7. Canato, E., Grigoletto, A., Zanotto, I., Tedeschini, T., Campara, B., Quaglio, G., ... & Pasut, G. (2023). Anti-HER2 Super Stealth Immunoliposomes for Targeted-Chemotherapy. *Advanced Healthcare Materials*, *12*(29), 2301650.
8. Carazo, E., Borrego-Sánchez, A., García-Villén, F., Sánchez-Espejo, R., Cerezo, P., Aguzzi, C., & Viseras, C. (2018). Advanced inorganic nanosystems for skin drug delivery. *The Chemical Record*, *18*(7-8), 891-899.
9. Celia, C., Cristiano, M. C., Froiio, F., Di Francesco, M., d'Avanzo, N., Di Marzio, L., & Fresta, M. (2021). Nanoliposomes as multidrug carrier of gemcitabine/paclitaxel

10.5281/zenedo.15960797

for the effective treatment of metastatic breast cancer disease: a comparison with Gemzar and Taxol. Advanced Therapeutics, 4(1), 2000121.

10. Chen, H., Zhang, Y., Yu, T., Song, G., Xu, T., Xin, T., ... & Han, B. (2022). Nano-based drug delivery systems for periodontal tissue regeneration. *Pharmaceutics*, *14*(10), 2250.
11. Cheng, L., & Wong, H. (2020). Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics, 12(7), 672.
12. Choudhury, H., Maheshwari, R., Pandey, M., Tekade, M., Gorain, B., & Tekade, R. K. (2020). Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug 'Etoposide'. *Materials Science and Engineering: C*, *106*, 110275.
13. Cristofoletti, R., Hens, B., Patel, N., Esteban, V. V., Schmidt, S., & Dressman, J. (2019). Integrating drug-and formulation-related properties with gastrointestinal tract variability using a product-specific particle size approach: case example ibuprofen. *Journal of Pharmaceutical Sciences*, *108*(12), 3842-3847.
14. Dahlgren, D., & Lennernäs, H. (2019). Intestinal permeability and drug absorption: predictive experimental, computational and in vivo approaches. *Pharmaceutics*, *11*(8), 411.
15. Datta, P., & Ray, S. (2020). Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties. *Journal of Labelled Compounds and Radiopharmaceuticals*, *63*(7), 333-355.
16. Deb, S., Reeves, A. A., & Lafortune, S. (2020). Simulation of physicochemical and pharmacokinetic properties of vitamin D3 and its natural derivatives. *Pharmaceuticals*, *13*(8), 160.
17. delMoral-Sanchez, J. M., Gonzalez-Alvarez, I., Gonzalez-Alvarez, M., Navarro, A., & Bermejo, M. (2019). Classification of WHO essential oral medicines for children applying a provisional pediatric biopharmaceutics classification system. *Pharmaceutics*, *11*(11), 567.
18. Denninger, A., Becker, T., Westedt, U., & Wagner, K. G. (2023). Advanced in vivo prediction by introducing biphasic dissolution data into PBPK models. *Pharmaceutics*, *15*(7), 1978.

10.5281/zenedo.15960797

19. Devasvaran, K., Jairaman, S., Yahaya, N. A., Jaganath, I. B. S., Khung, Y. L., Lim, V., & Ngalim, S. H. (2020). PEG-b-PLGA nanoparticles loaded with geraniin from *Phyllanthus watsonii* extract as a phytochemical delivery model. *Applied Sciences, 10*(14), 4891.

20. Dewanjee, S., Chakraborty, P., Mukherjee, B., & De Feo, V. (2020). Plant-based antidiabetic nanoformulations: the emerging paradigm for effective therapy. *International journal of molecular sciences*, *21*(6), 2217.